Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
- Barbara Pro
- , Ranjana Advani
- , Pauline Brice
- , Nancy L. Bartlett
- , Joseph D. Rosenblatt
- , Tim Illidge
- , Jeffrey Matous
- , Radhakrishnan Ramchandren
- , Michelle Fanale
- , Joseph M. Connors
- , Yin Yang
- , Eric L. Sievers
- , Dana A. Kennedy
- , Andrei Shustov
Research output: Contribution to journal › Article › peer-review